Skip to content

GLUE

Monte Rosa Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$23.48-4.40%

Price as of Jul 20, 2026

GLUE capital

Monte Rosa Therapeutics, Inc. capital & dividend

Leverage, liquidity, debt coverage and shareholder-distribution metrics.

Leverage

Debt / equity
0.07x
Net debt / equity
-0.23x
Debt / assets
0.05x
Debt / EBITDA
-0.32x
Net debt / EBITDA
0.98x

Liquidity & coverage

Current ratio
9.54x
Quick ratio
9.54x
Cash ratio
9.38x
Interest coverage
EBITDA / interest
Working capital
$606.5M

Cash & dividend

FCF / debt
-0.50x
Cash flow / debt
-0.38x
Dividend per share
Dividend yield
Dividend growth 1y

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.